Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability.

Article Details

Citation
Copy to clipboard

Gilfrich HJ, Kremer G, Mohrke W, Mutschler E, Volger KD

Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability.

Eur J Clin Pharmacol. 1983;25(2):237-41.

PubMed ID
6628507 [ View in PubMed
]
Abstract

With a new formulation, which made intravenous infusion of triamterene (TA) possible, plasma levels and urinary excretion rates of TA and its main metabolite (OH-TA-ester) were measured in a randomized, cross-over trial in 6 healthy volunteers given triamterene 10 mg i.v. and 50 mg p.o. TA and OH-TA-ester were determined by densitometric measurement of native fluorescence after thin layer chromatography. Distribution volumes of the central compartment of TA and OH-TA-ester were 1.49 l/kg and 0.11 l/kg, respectively. Terminal half-lives were 255 min for TA and 188 min for OH-TA-ester after i.v. administration. For TA total plasma clearance was 4.5 l/min and renal plasma clearance 0.22 l/kg. The formation of OH-TA-ester was very rapid and the concentration of the metabolite exceeded that of TA at all times. After i.v. administration the urinary recovery of TA and OH-TA-ester was 4.4% and 50.9%, respectively. The bioavailability of TA was 52%, corresponding to absorption of 83%. TA is partly eliminated by a first-pass-effect. The main metabolite of TA is OH-TA-ester, which is pharmacologically active.

DrugBank Data that Cites this Article

Drugs